Emicizumab prophylaxis vs immune tolerance induction in children with severe hemophilia A and inhibitors: a retrospective comparison of bleeding control, quality of life, and cost

Read full text Summarise with VIRAT
Authors: Zhengping Li, Qianqian Mao, Gang Li, Xiaoling Cheng, Yingzi Zhen, Guoqing Liu, Wanru Yao, Zekun Li, J L Zhang, Shuyue Dong, Di Ai, Zhenping Chen
+1 more Runhui Wu
Cited by: 0
References: 23

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background There is limited evidence directly comparing emicizumab (EMI) prophylaxis and immune tolerance induction (ITI) in children with severe hemophilia A and high-titer inhibitors (SHAcwHTI), particularly bleeding control, quality of life (QoL), and cost. Objectives This study compared outcomes of EMI vs ITI in SHAcwHTI, focusing on bleeding rates, QoL, and costs. Methods This single-center retrospective study enrolled SHA children (inhibitor titer ≥5 Bethesda Units/mL), receiving EMI or ITI from January 2020 to December 2024. EMI included loading (initial 4 weeks) and maintenance doses; ITI involved intermediate-dose (factor [F]VIII 100 IU/kg/d) or low-dose (FVIII 50 IU/kg once every other day). Outcomes included annualized bleeding rate (ABR), annualized joint bleeding rate (AJBR), Canadian Hemophilia Outcomes-Kids Life Assessment Tool scores, and medication costs. Results Among 140 patients (24 in EMI group and 116 in ITI group [40 intermediate-dose ITI and 76 low-dose ITI]), EMI was associated with better bleeding control: median ABR and AJBR were 0 across all observation periods, significantly lower than ITI. For ITI, both ABR and AJBR declined over time but remained higher than those of EMI group. Target joint proportion decreased most markedly in patients receiving EMI (35.7%-0%; P = 0.002). EMI group also showed greater QoL improvement (mean change in parent proxy-reported Canadian Hemophilia Outcomes-Kids Life Assessment Tool scores: +26.6 vs +19.2 vs +19.1; P < .001) and lower medication costs (1993.4 vs 3703.4 vs 3656.3 US$/kg; P < .001). Conclusions EMI prophylaxis was associated with improved bleeding control and QoL while reduced costs compared with ITI, offering a valuable option for SHAcwHTI, prioritizing immediate hemostasis over the long-term goal of inhibitor eradication, especially in resource-limited settings.

Fields of Study & Subjects

Hemophilia Treatment and Research Platelet Disorders and Treatments Coagulation Bradykinin Polyphosphates and Angioedema

Publication details

Journal / source
Research and Practice in Thrombosis and Haemostasis
Volume
10
Issue
3
Pages
103425–103425
Publication date
1 March 2026
Language
EN